Moderna, Inc.
MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026Score 5/30573% above fair value
$220.83−0.89 (-0.40%)
Close on Nov 2, 2026Market cap $88.16BP/E –Yield –
Moderna Upfront licensing & in-process R&D milestone payments by Quarter
Upfront licensing & in-process R&D (IPR&D) milestone payments ($M) ($M)
Moderna Upfront licensing & in-process R&D milestone payments: $11M in Q2 2026, up 83.3% from a year earlier.
Latest, Q2 2026
11
Period ended Jun 30, 2026
Change on a year earlier
+83.3%
6 in Q2 2025
History
22 quarters
Since Q1 2021
Sources
17
Documents cited below
Where the Q2 2026 figure comes from
Source: Form 10-Q (filed 2026-07-31) ↗
Reported in Form 10-Q / 10-K Consolidated Statements of Cash Flows.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Upfront licensing & in-process R&D (IPR&D) milestone payments ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 11 | +83.3% | Form 10-Q (filed 2026-07-31) ↗ |
| Q1 2026 | Mar 31, 2026 | 895 | +17,800.0% | Form 10-Q (filed 2026-05-01) ↗ |
| Q4 2025 | Dec 31, 2025 | 34 | -24.4% | Form 10-K (filed 2026-02-20) ↗ |
| Q3 2025 | Sep 30, 2025 | 43 | -53.3% | Form 10-Q (filed 2025-11-06) ↗ |
| Q2 2025 | Jun 30, 2025 | 6 | -40.0% | Form 10-Q (filed 2026-07-31) ↗ |
| Q1 2025 | Mar 31, 2025 | 5 | -37.5% | Form 10-Q (filed 2026-05-01) ↗ |
| Q4 2024 | Dec 31, 2024 | 45 | -64.0% | Form 10-K (filed 2026-02-20) ↗ |
| Q3 2024 | Sep 30, 2024 | 92 | +17.9% | Form 10-Q (filed 2025-11-06) ↗ |
| Q2 2024 | Jun 30, 2024 | 10 | -16.7% | Form 10-Q (filed 2025-08-01) ↗ |
| Q1 2024 | Mar 31, 2024 | 8 | -90.7% | Form 10-Q (filed 2025-05-01) ↗ |
| Q4 2023 | Dec 31, 2023 | 125 | -80.2% | Form 10-K (filed 2026-02-20) ↗ |
| Q3 2023 | Sep 30, 2023 | 78 | -26.4% | Form 10-Q (filed 2024-11-07) ↗ |
| Q2 2023 | Jun 30, 2023 | 12 | -92.4% | Form 10-Q (filed 2024-08-01) ↗ |
| Q1 2023 | Mar 31, 2023 | 86 | -58.5% | Form 10-Q (filed 2024-05-02) ↗ |
| Q4 2022 | Dec 31, 2022 | 630 | +161.4% | Form 10-K (filed 2025-02-21) ↗ |
| Q3 2022 | Sep 30, 2022 | 106 | -36.9% | Form 10-Q (filed 2023-11-03) ↗ |
| Q2 2022 | Jun 30, 2022 | 157 | +6.1% | Form 10-Q (filed 2023-08-03) ↗ |
| Q1 2022 | Mar 31, 2022 | 207 | +146.4% | Form 10-Q (filed 2023-05-04) ↗ |
| Q4 2021 | Dec 31, 2021 | 241 | – | Form 10-K (filed 2024-02-23) ↗ |
| Q3 2021 | Sep 30, 2021 | 168 | – | Form 10-Q (filed 2022-11-03) ↗ |
| Q2 2021 | Jun 30, 2021 | 148 | – | Form 10-Q (filed 2022-08-03) ↗ |
| Q1 2021 | Mar 31, 2021 | 84 | – | Form 10-Q (filed 2022-05-04) ↗ |
Cite this data
StockData. (2026). Moderna Upfront licensing & in-process R&D milestone payments ($M), quarterly Q1 2021–Q2 2026 [Data set]. Compiled from Moderna SEC filings and investor materials. https://stockdatahq.com/stocks/mrna/kpis/iprd-paid
See every metric in the Moderna KPI table. Data updated Nov 3, 2026.